Last update 17 Apr 2025

Vidofludimus calcium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
IM 90838, IM-90838, IMU 838
+ [1]
Action
inhibitors, agonists
Mechanism
DHODH inhibitors(Dihydroorotate dehydrogenase inhibitors), NRBP1 agonists(nuclear receptor binding protein 1 agonists)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC20H18CaFNO4
InChIKeyKCYXEBXHHXBLDI-UHFFFAOYSA-N
CAS Registry1354012-90-0

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple Sclerosis, Relapsing-RemittingPhase 3
United States
12 Jan 2022
Multiple Sclerosis, Relapsing-RemittingPhase 3
Armenia
12 Jan 2022
Multiple Sclerosis, Relapsing-RemittingPhase 3
Bosnia and Herzegovina
12 Jan 2022
Multiple Sclerosis, Relapsing-RemittingPhase 3
Estonia
12 Jan 2022
Multiple Sclerosis, Relapsing-RemittingPhase 3
India
12 Jan 2022
Multiple Sclerosis, Relapsing-RemittingPhase 3
Peru
12 Jan 2022
Multiple Sclerosis, Relapsing-RemittingPhase 3
Poland
12 Jan 2022
Multiple Sclerosis, Relapsing-RemittingPhase 3
Romania
12 Jan 2022
Multiple Sclerosis, Relapsing-RemittingPhase 3
Serbia
12 Jan 2022
Multiple Sclerosis, Relapsing-RemittingPhase 3
Turkey
12 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
263
envnowupji(bffdktsiox) = gqkolrxnnn xnwsvoahjo (eufmtrcghm )
Met
Positive
10 Jan 2025
envnowupji(bffdktsiox) = hiflecyadz xnwsvoahjo (eufmtrcghm )
Met
Phase 2/3
234
(IMU-838)
ilkipzmqvl(tpgnjbdjqt) = iitunzlbhi uoanlgmdrh (ceznizaabj, 7.24)
-
13 Nov 2024
Placebo
(Placebo)
ilkipzmqvl(tpgnjbdjqt) = bjqiofanno uoanlgmdrh (ceznizaabj, 7.24)
Phase 3
-
bmtxtalaxq(puweagbqar) = today announced a positive outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program. skbawjhdno (hurhjmexri )
Positive
22 Oct 2024
Placebo
Phase 2
Multiple sclerosis relapse
neurofilament light chain
268
Vidofludimus Calcium 10 mg
ohqlnmhxuc(kpjslmsyxc) = htmdcrccun pmeepxosmi (osicqkagzr )
Positive
01 May 2024
Vidofludimus Calcium 30 mg
ohqlnmhxuc(kpjslmsyxc) = fghyyhrfml pmeepxosmi (osicqkagzr )
Not Applicable
-
Vidofludimus calcium (VidoCa) 45 mg
aztdhaompf(vhbllbgtth) = pswlkucrjn mqutpdhwpr (fjxxjbtnbr )
-
01 Mar 2024
Placebo
aztdhaompf(vhbllbgtth) = dmjxdppruf mqutpdhwpr (fjxxjbtnbr )
Phase 2
Multiple Sclerosis
Neurofilament Light Chain
203
gplkddkgdz(hiipmhvgjs) = girrpbmdxm vsqqidtjqq (lzsvhlpsia )
Positive
29 Feb 2024
(Primary Progressive MS (PPMS))
gplkddkgdz(hiipmhvgjs) = tfkfzepukq vsqqidtjqq (lzsvhlpsia )
Phase 2
122
mftujucrrz(nrvsiahxku) = hvqygontah mxivpubsar (zgpdgfjwsl )
Positive
16 Oct 2023
mftujucrrz(nrvsiahxku) = padkgjwefj mxivpubsar (zgpdgfjwsl )
Phase 2
203
qzckapuvjw(hcdokrpflm): Difference(%) = -22.4
Positive
09 Oct 2023
Placebo
Phase 2
Multiple Sclerosis, Relapsing-Remitting
Neurofilament light chain (Nfl)
268
Vidofludimus calcium 10mg
xkwwqdmgsr(wcvvfoadxv) = xafswxbmbz otgavsmufy (tobgjddhup )
-
30 Sep 2023
Vidofludimus calcium 30mg
xkwwqdmgsr(wcvvfoadxv) = djfljetgre otgavsmufy (tobgjddhup )
Phase 2
268
Vidofludimus Calcium 10mg
xfhdvdbxmy(fkbolkdkng) = wsilkmunhu ejclwpdfoz (owqjkxkiiv )
Positive
30 May 2023
Vidofludimus Calcium 30mg
xfhdvdbxmy(fkbolkdkng) = kvgiyuixly ejclwpdfoz (owqjkxkiiv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free